Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4610694 | 1.00 | CHRM2 (0.49) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL31280907 | 0.81 | PDE2A (0.45) | DRD2ADRA2BDRD1HTR2AHTR2C | |
| SCHEMBL6273482 | 0.81 | CTSA (0.44) | HTR2C | |
| SCHEMBL18306406 | 0.80 | HTR2B (0.58) | DRD2ADRA2BDRD1HTR2AHTR2C | |
| SCHEMBL14862503 | 0.77 | CA1 (0.44) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7259231 | 0.77 | CA1 (0.60) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3048141 | 0.76 | HTR2C (0.55) | DRD2ADRA2BDRD1HTR2AHTR2C | |
| SCHEMBL6452038 | 0.76 | ALDH1A1 (0.39) | TSHRPOLB | |
| SCHEMBL3048145 | 0.76 | HTR2C (0.55) | DRD2ADRA2BDRD1HTR2AHTR2C | |
| SCHEMBL4225398 | 0.76 | HTR2C (0.55) | DRD2ADRA2BDRD1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1308436-B1 | CALCIUM RECEPTOR ANTAGONISTS | JAPAN TOBACCO INC (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-7211685-B2 | Calcium receptor antagonists | JAPAN TOBACCO INC. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-7211685-B2 | Calcium receptor antagonists | JAPAN TOBACCO INC. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-7211685-B2 | Calcium receptor antagonists | JAPAN TOBACCO INC. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-6916956-B2 | Calcium receptor antagonist | JAPAN TOBACCO, INC. (JP) | 2005-07-12 | — | — | US | disclosed |
| US-20050107448-A1 | Calcium receptor antagonists | JAPAN TABACCO INC. | 2005-05-19 | — | — | US | disclosed |
| US-20040006130-A1 | Calcium receptor antagonist | JAPAN TOBACCO INC (JP) | 2004-01-08 | — | — | US | disclosed |
| EP-1308436-A1 | CALCIUM RECEPTOR ANTAGONISTS | JAPAN TOBACCO INC. (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107448-A1 | Calcium receptor antagonists | CASR, CALCR, CALCRL | CHRM2 166/4885CHRM4 731/4885CHRM5 406/4885 |
| US-20040006130-A1 | Calcium receptor antagonist | CALCRL, CASR, CALCR | CHRM2 847/4885CHRM4 2092/4885CHRM5 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.